Search

Your search keyword '"Coso D"' showing total 231 results
Start Over Author "Coso D" Language english
231 results on '"Coso D"'

13. Understanding the protective effects of wine components and their metabolites in the brain function

Author

Esteban-Fernández A., Gigorro del Coso D., González de Llano D., Spencer J., Bartolomé B., and Moreno-Arribas M.V.

Subjects
Microbiology, QR1-502, Physiology, QP1-981, Zoology, QL1-991
Abstract

Moderate wine consumption has been suggested to exert a positive effect in prevention of neurodegenerative process and cognitive impairment. With the ultimate aim of achieving a better understanding of the molecular mechanisms behind this benefit, we have investigated the role of certain wine- derived phenolic metabolites and aroma compounds in the MAPK cascade (including ERK1/2, p38), one of the routes directly related to inflammation in neuronal cells. Some of the tested phenolic compounds, especially in the case of 3,4-dihydroxyphenylacetic acid, showed a significant neuroprotective effect against SIN-1-induced neuronal death. Regarding their effect over MAPK phosphorylation, inmunoblotting technique revealed a beneficial and significant decrease on the phosphorylation of p38 and ERK1/2 kinases after incubation with wine constituents. In addition, activity of caspase3-like protease, an executor of neuronal apoptosis and a downstream signal of MAPK, was significantly diminished by 3-(3-hydroxyphenyl) propionic acid and linalool, counterbalancing the increase produced by SIN-1. Altogether, these results suggest that wine aroma, phenolic compounds and their gut metabolites could exert neuroprotective actions by modulating MAPK signalling and caspase-3 proteases activation, which are known to play a key role in oxidative/ nitrosative stress-induced response.

Published
2016
Full Text
View/download PDF

14. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

Author

Delannoy, A, Delabesse, E, Lhéritier, V, Castaigne, S, Rigal-Huguet, F, Raffoux, E, Garban, F, Legrand, O, Bologna, S, Dubruille, V, Turlure, P, Reman, O, Delain, M, Isnard, F, Coso, D, Raby, P, Buzyn, A, Caillères, S, Darre, S, Fohrer, C, Sonet, A, Bilhou-Nabera, C, Béné, M-C, Dombret, H, Berthaud, P, and Thomas, X

Published
2006
Full Text
View/download PDF

20. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase

Author

Maloisel, F, Guerci, A, Guyotat, D, Ifrah, N, Michallet, M, Reiffers, J, Tertain, G, Blanc, M, Bauduer, F, Brière, J, Abgrall, JF, Pegourie-Bandelier, B, Solary, E, Cambier, N, Coso, D, Vilque, JP, Delain, M, Harousseau, JL, Rousselot, P, Belhadj, K, Morice, P, Attal, J, Chabin, M, Chastang, C, Guilhot, J, and Guilhot, F

Published
2002
Full Text
View/download PDF

40. Clinical and biological aspects of aggressive B-cell non-Hodgkin lymphoma in adolescents and young adults

Author

Coso D, Garciaz S, and Bouabdallah R

Subjects
immune system diseases, hemic and lymphatic diseases, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract

Diane Coso, Sylvain Garciaz, Réda BouabdallahDepartment of Hematology, Cancer Center Institut J. Paoli-I. Calmettes, University of La Méditerranée, Marseille, FranceAbstract: Non-Hodgkin lymphomas (NHLs) are one of the most frequent malignancies in adolescents and young adults (AYA). Among NHLs, Burkitt's lymphoma (BL) represents approximately 40% while diffuse large B-cell lymphoma (DLBCL) accounts for nearly 20% of cases. Primary mediastinal B-cell lymphoma is a variant of DLBCL, which preferentially concerns young patients. Biology of B-NHLs is well known and several pathways involving chromosomal translocations, gene rearrangements, and molecular profiling are the subject of continuous investigations. AYA with B-NHL have inferior survival when compared with children. The reasons for this unfavorable outcome are multifactorial, but disease-related biological characteristics of the tumor represent a powerful factor influencing survival. The choice of optimal strategy in the management of B-NHL in patients of 15–29 years old remains controversial and depends on the treating institution and its physicians. Although children and younger adolescents benefit from pediatric approaches using intensive treatment, older adolescents are often treated with adult rituximab-based chemotherapy. In this review, we focus on the current knowledge relevant to AYA with DLBCL and primary mediastinal B-cell lymphoma.Keywords: DLBCL, PMBCL, AYA, prognosis, treatment

Published
2015

42. A conditioning platform based on fludarabine, busulfan and two days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor

Author

Devillier, R., Fürst, S., Crocchiolo, R., El-Cheikh, J., Castagna, L., Harbi, S., Granata, A., D'Incan, E., Coso, D., Chabannon, C., Picard, C., Etienne, A., Calmels, B., Schiano, J. M., Lemarie, C., Stoppa, A. M., Bouabdallah, R., Vey, N., Blaise, D., Hematology and BMT Unit, San Raffaele Scientific Institute, Unit of Lymphoid Malignancies, Biostatistics Unit, Università degli studi di Genova = University of Genoa (UniGe), Hematology and BMT Unit, Unit of Lymphoid Malignancies, Department of Oncology, Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, and University of Genoa (UNIGE)

Subjects
parasitic diseases, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Abstract

International audience; : Conditioning regimen including fludarabine (FLU), intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG), results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N=74) or MMUD (N=40). We compared outcome of MUD vs. MMUD patients. There was no difference in the cumulative incidence of grade II-IV acute GVHD (MUD: 34% vs. MMUD: 35%, p=0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5% vs. MMUD: 15%, p=0.016). The cumulative incidences of overall chronic GVHD (MUD: 33% vs. MMUD: 22%, p=0.088) and extensive chronic GVHD (MUD: 20% vs. MMUD: 19%, p=0.594) were comparable. One-year NRM was similar in both groups (MUD: 16% vs. MMUD: 14%, p=0.292); similarly, progression-free survival (MUD: 59% vs. MMUD: 55%, p=0.476) and overall survival (MUD: 63% vs. MMUD: 61%, p=0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47%) and 19 of 40 MMUD patients (48%) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients.

Published
2014

46. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.

Author

Maloisel, F., Guerci, A., Guyotat, D, Ifrah, N, Michallet, M, Reiffers, J, Tertain, G, Blanc, M, Bauduer, F, Brière, J, Abgrall, J F, Pegourie-Bandelier, B, Solary, E, Cambier, N, Coso, D, Vilque, J P, Delain, M, Harousseau, J L, Rousselot, P, and Belhadj, K

Subjects
LEUKEMIA treatment, MYELOID leukemia, LEUKEMIA
Abstract

Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to systemic deamination after oral administration. Following initial studies indicating significant anti-tumour activity of YNK01 a phase II trial was initiated in order to assess the tolerability and efficacy of a combination of this agent with interferon alpha-2b (IFN-alpha2b) in recently diagnosed chronic phase CML patients (n = 98). The treatment was subdivided into cycles consisting of 4 weeks of continuous administration of IFN-alpha-2b (3 MU/m(2)/day 1st week and then 5 MU/m(2)/day) and 14 days of oral YNK01 (600 mg/day 1st cycle). At the end of each cycle the dose of YNK01 was adjusted according to the blood count observed during the previous 4 weeks. The median time from diagnosis to inclusion in the trial was 2 months (range 6 days to 7.5 months). At 12 weeks, 62 patients (63%; 95% CI, 54-73) achieved a complete hematological response. At 24 weeks, of 98 patients, two achieved a complete cytogenetic response, 14 a partial response (16% major cytogenetic response rate; 95% CI, 9-24) and 34 a minor response; 19 patients were not evaluable for cytogenetic response. During the trial, 20 patients progressed to accelerated (6) or blastic phases (14). The median time to progression was 15 months (range 2-38 months). At 3 years the overall survival was 79% (95% CI, 70-88). Although the complete hematological response rate compared favorably with the 40% response rate previously obtained with the subcutaneous formulation of Ara-c, the cytogenetic response rate was less than expected. Most of the patients experienced side-effects and all permanently stopped YNK01. Although the combination seems attractive the initial dose of 600 mg per day is probably too high and should be reconsidered in further trials. [ABSTRACT FROM AUTHOR]

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results